| 8.48 -0.25 (-2.86%) | 11-20 16:00 | |||||||||||||
|
|
| Short term | |
|||
| Mid term | |
|||
| Targets | 6-month : | 12.61 |
1-year : | 14.3 |
| Resists | First : | 10.8 |
Second : | 12.25 |
| Pivot price | 10.25 |
|||
| Supports | First : | 8.45 |
Second : | 7.03 |
| MAs | MA(5) : | 8.93 |
MA(20) : | 10.56 |
| MA(100) : | 13.42 |
MA(250) : | 13.06 |
|
| MACD | MACD : | -0.9 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 1.5 |
D(3) : | 2.5 |
| RSI | RSI(14): 27.9 |
|||
| 52-week | High : | 17.39 | Low : | 7.3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BWAY ] has closed above bottom band by 6.5%. Bollinger Bands are 93.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.78 - 8.86 | 8.86 - 8.91 |
| Low: | 8.28 - 8.39 | 8.39 - 8.45 |
| Close: | 8.36 - 8.53 | 8.53 - 8.64 |
Established in Jerusalem, Israel, in 2003, BrainsWay Ltd. specializes globally in creating and distributing advanced, non-invasive neurostimulation therapies designed to address a wide array of mental health and neurological conditions. The company's primary innovation is its Deep Transcranial Magnetic Stimulation (dTMS) platform, which offers treatment for disorders including major and anxious depression, obsessive-compulsive disorder, nicotine addiction, bipolar disorder, post-traumatic stress disorder, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's solutions are primarily adopted by psychiatric practitioners, hospitals, and medical centers across the United States, Europe, Israel, and other international markets.
Thu, 10 Sep 2026
BrainsWay’s (BWAY) Growth Streak Just Got Harder To Ignore - Yahoo Finance
Thu, 27 Aug 2026
Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High? - Yahoo Finance
Mon, 17 Aug 2026
Brainsway (BWAY) Upgraded to Buy: Here's Why - Yahoo Finance
Thu, 13 Aug 2026
BrainsWay: Market Saturation And Competition Could Be Issues (NASDAQ:BWAY) - Seeking Alpha
Tue, 26 May 2026
BWAY - Brainsway Ltd ADR Stock Price and Quote - Finviz
Mon, 13 Apr 2026
Brainsway (BWAY) Is a Great Choice for 'Trend' Investors, Here's Why - qz.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Specialties
|
|
| Shares Out | 40 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 6 (%) |
| Held by Institutions | 29.3 (%) |
| Shares Short | 226 (K) |
| Shares Short P.Month | 200 (K) |
| EPS | 0.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.97 |
| Profit Margin | 15.5 % |
| Operating Margin | 13.9 % |
| Return on Assets (ttm) | 4 % |
| Return on Equity (ttm) | 12.8 % |
| Qtrly Rev. Growth | 35.4 % |
| Gross Profit (p.s.) | 1.13 |
| Sales Per Share | 1.5 |
| EBITDA (p.s.) | 0.21 |
| Qtrly Earnings Growth | 59.7 % |
| Operating Cash Flow | 8 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | 36.86 |
| PEG Ratio | 0 |
| Price to Book value | 4.3 |
| Price to Sales | 5.62 |
| Price to Cash Flow | 45.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |